PT - JOURNAL ARTICLE AU - Alders, Nele AU - Penner, Justin AU - Grant, Karlie AU - Patterson, Charlotte AU - Hassell, Jane AU - MacDermott, Nathalie AU - Pincott, Sian AU - Bamford, Alasdair AU - Pré, Pascale du AU - Johnson, Mae AU - Moshal, Karyn TI - COVID-19 Pandemic Preparedness in a United Kingdom Tertiary and Quaternary Children’s Hospital: Tales of the Unexpected AID - 10.1101/2020.08.20.20178541 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.20.20178541 4099 - http://medrxiv.org/content/early/2020/08/22/2020.08.20.20178541.short 4100 - http://medrxiv.org/content/early/2020/08/22/2020.08.20.20178541.full AB - Background The paucity of data describing SARS-CoV-2 in the paediatric population necessitated a broad-arching approach to pandemic planning, with preparations put in place to manage a heterogeneous cohort. We describe a diverse group of SARS-CoV-2 positive paediatric patients treated at a large tertiary/quaternary children’s hospital in the United Kingdom and the adaptive coping strategies required.Methods All paediatric patients with positive RT-PCR on a respiratory sample and/or serology for SARS-CoV-2 up to 19th May 2020 were included.Results 57 children met the inclusion criteria. 70% were of non-Caucasian ethnicity with a median age of 9.3 years (IQR 5.16–13.48). Four distinct groups were identified: paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) (54%), primary respiratory (18%), incidental (7%), and non-specific febrile illnesses with or without extra-pulmonary organ dysfunction (21%). These groups presented in distinct chronological blocks as the pandemic unfolded.Discussion The diverse range of presentations of SARS-CoV-2 infection in this population exemplified the importance of preparedness for the unknown in the midst of a novel infectious pandemic. Descriptions of paediatric patients during the initial phase of the pandemic from other parts of the globe and extrapolation from adult data did not serve as an accurate representation of paediatric COVID-19 in our centre. An adaptive, multidisciplinary approach was paramount. Expanded laboratory testing and incorporation of technology platforms to facilitate remote collaboration in response to strict infection control precautions were both indispensable. Lessons learned during the preparation process will be essential in planning for a potential second wave of SARS-CoV-2.Competing Interest StatementAB received funds for consultative work provided to Gilead Sciences Inc. This consultative work did not impact on the results of the manuscript submitted. No conflicts of interest declared.Clinical TrialThe project was registered with the local research department (approval #2857)Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was registered with the local research department (approval #2857)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymised data was collected and stored in a secure Excel database